TP53 and familial pancreatic carcinoma: More recently, the incorporation of an aryl-carbamate moiety at the C-14 position has yielded derivatives with potent anti-pancreatic cancer activity, attributed to downregulation of oncogenic p53 expression and inhibition of multiple malignant phenotypes in pancreatic cancer models [28].